(Q36711373)

15 August 2017

1 reference

title

5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis (English)

1 reference

15 August 2017

Aapro MS

1

1 reference

15 August 2017

1 October 1991

1 reference

15 August 2017

1 reference

15 August 2017

42

1 reference

15 August 2017

551-568

1 reference

15 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199142040-00002

15 August 2017

0 references

cites work

Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.

1 reference

12 December 2020

Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis

1 reference

12 December 2020

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

1 reference

12 December 2020

An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy

1 reference

12 December 2020

BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons

1 reference

12 December 2020

The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons

1 reference

12 December 2020

Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930.

1 reference

12 December 2020

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

12 December 2020

The metabolism of ondansetron

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group

1 reference

12 December 2020

Pharmacological analysis of the effects of metoclopramide on the guinea-pig ileum in vitro

1 reference

12 December 2020

Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Ondansetron. Therapeutic use as an antiemetic

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor

1 reference

12 December 2020

The clinical utility of pharmacological agents that act at serotonin receptors

1 reference

12 December 2020

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

1 reference

12 December 2020

Basic mechanisms of antimigraine drugs

1 reference

12 December 2020

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

12 December 2020

MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

1 reference

12 December 2020

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

12 December 2020

Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat

1 reference

12 December 2020

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

1 reference

12 December 2020

RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog

1 reference

12 December 2020

The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.

1 reference

12 December 2020

Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting

1 reference

12 December 2020

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

12 December 2020

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

12 December 2020

The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist

1 reference

12 December 2020

Clinical evaluation of 5-HT3 receptor antagonists as anti-emetics

1 reference

12 December 2020

Correlation of anti-emetic efficacy and plasma levels of ondansetron

1 reference

12 December 2020

Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.

1 reference

12 December 2020

Evidence for an extra-abdominal site of action for the 5-HT3 receptor antagonist BRL24924 in the inhibition of radiation-evoked emesis in the ferret

1 reference

12 December 2020

The effect of three dose levels of ICS 205-930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting.

1 reference

12 December 2020

Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor.

1 reference

12 December 2020

Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors

1 reference

12 December 2020

5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment

1 reference

12 December 2020

A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.

1 reference

12 December 2020

Safety of ondansetron

1 reference

12 December 2020

Specific [3H]LY278584 binding to 5-HT3 recognition sites in rat cerebral cortex

1 reference

12 December 2020

Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret

1 reference

12 December 2020

Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist

1 reference

12 December 2020

Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic

1 reference

12 December 2020

The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.

1 reference

12 December 2020

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

1 reference

12 December 2020

Two kinds of tryptamine receptor

1 reference

12 December 2020

A single-dose-finding study of the antiemetic effect and associated plasma levels of MDL 72222 in patients receiving cisplatin

1 reference

12 December 2020

Effects of metoclopramide on isolated guinea-pig colon. 2)Interference with ganglionic stimulant drugs

1 reference

12 December 2020

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine

1 reference

12 December 2020

Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients

1 reference

12 December 2020

Adverse reaction to 5-HT3 antagonist ICS 205930

1 reference

12 December 2020

Pharmacological and anti-emetic properties of ondansetron.

1 reference

12 December 2020

Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia

1 reference

12 December 2020

BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties

1 reference

12 December 2020

Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives.

1 reference

12 December 2020

3HQuaternised ICS 205-930 labels 5-HT3 receptor binding sites in rat brain

1 reference

12 December 2020

Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

1 reference

12 December 2020

The 5-HT3 receptor antagonists ICS 205-930 and GR38032F, putative anxiolytic drugs, differ from diazepam in their pharmacological profile

1 reference

12 December 2020

Clinical studies with ondansetron in the control of radiation-induced emesis.

1 reference

12 December 2020

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

12 December 2020

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

12 December 2020

The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin

1 reference

12 December 2020

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine

1 reference

12 December 2020

BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy

1 reference

12 December 2020

Evidence for two types of 5-hydroxytryptamine receptor on secretomotor neurons of the guinea-pig ileum.

1 reference

12 December 2020

The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

1 reference

12 December 2020

Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

1 reference

12 December 2020

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Zacopride, a potent 5-HT3 antagonist

1 reference

12 December 2020

GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

1 reference

12 December 2020

The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity

1 reference

12 December 2020

5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum

1 reference

12 December 2020

5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930.

1 reference

12 December 2020

LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity.

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis

1 reference

12 December 2020

[3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.

1 reference

12 December 2020

Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?

1 reference

12 December 2020

The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist

1 reference

12 December 2020

The antiemetic profile of zacopride

1 reference

12 December 2020

Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801)

1 reference

12 December 2020

Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS

1 reference

12 December 2020

5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis

1 reference

12 December 2020

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy

1 reference

12 December 2020

Antiemetics: neurotransmitter receptor binding predicts therapeutic actions

1 reference

12 December 2020

The clinical pharmacology of ondansetron

1 reference

12 December 2020

The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis

1 reference

12 December 2020

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS

1 reference

12 December 2020

Developments in the antiemetic area: chemistry, pharmacology and therapy

1 reference

12 December 2020

The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice

1 reference

12 December 2020

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

12 December 2020

First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis

1 reference

12 December 2020

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

12 December 2020

10.2165/00003495-199142040-00002

Identifiers

DOI

1 reference

PubMed ID

1723361

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

1723361